Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine after reduced-intensity allogeneic transplant for AML or MDS
ISRCTN36825171Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Birmingham. Primary endpoint: Safety of azacitidine treatment. Started Jun 2008; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN36825171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36825171.